Domain | Rank | Visitors | Earning per month | Valuation |
gskpro.com | 202824 | 8,190 | 914$ | 27420$ |
gsksource.com | None | 0 | 0$ | 1000$ |
astrazeneca.com | 35012 | 4,803 | 2,368$ | 71040$ |
novartis.com | 73511 | 16,616 | 2,936$ | 88080$ |
sanofi.com | 81025 | 6,180 | 1,207$ | 36210$ |
gsk.co.uk | 4694167 | 0 | 0$ | 1000$ |
gskdirect.com | 3623728 | 2,722 | 253$ | 7590$ |
packageinsert.jp | 1360929 | 1,947 | 181$ | 5430$ |
Moz Backlinks Count | None |
Moz Page Rank | 4 |
Domain Authority (DA) | 51.0 |
Page Authority (PA) | 35.0 |
Country | Rank | Pct |
---|
Country Name | United Kingdom |
Country Rank | 10631 3776 |
Daily unique visits | 17,183 |
Daily Page Views | 41,239 |
Income Per Day | 3,835 USD |
Gsk.com valuation | 115050 |
No | Text |
1 | A new era for human health |
2 | Discover how we're getting ahead |
3 | How we help people thrive |
4 | Outstanding people |
5 | GSK on social |
No | Text |
1 | We make innovative vaccines and specialty medicines to prevent and treat disease. Our R&D focuses on the science of the immune system, human genetics and advanced technologies. |
2 | Unlocking the power of the immune system to get ahead of hepatitis B |
3 | Tackling tomorrow’s health challenges today |
4 | How vaccine science can help tackle antimicrobial resistance |
5 | The 40 year fight against HIV |
6 | How the next generation of immuno-oncology could help us get ahead of cancer |
7 | 1.4 million reasons to get ahead of gynaecologic cancers |
8 | Digital twin: using advanced technology to accelerate vaccine development |
9 | What if remission were the target of lupus care? |
10 | Synthetic Lethality: accelerating precision cancer treatments |
11 | Tech for T-cells single cell RNA seq measures shifts in immune cells to pinpoint causes of disease |
12 | Share price at 19 August 2022 16:45 |
13 | Share price at 23 August 2022 10:29 |
No | Text |
1 | Behind the science |
2 | Life at GSK |